Skip to Content
Home > Care & Treatment > Payson Center for Cancer Care > Clinical Trials > Clinical Trials Search Results
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
This study split participants into two groups. One will receive Vitamin D and the other will receive placebo to try to confirm if this is true.
© 2015 Concord Hospital